Biorelate secures £6.5m in Series A funding led by Maven Capital Partners and YFM Equity Partners to drive expansion

The financing round was backed by Maven Capital Partners, YFM Equity Partners, Triple Point Ventures, and regional funds to support US growth.
"Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics. Equally, we are at a time where there is a stupendous amount of untapped evidence, like cause-and-effect, sat dark and subsequently unused by these same companies. Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions and speed up the drug discovery process."


